An implantable device that narrows the coronary sinus appears to be a good option for patients with refractory angina who are not candidates for further revascularization, real-world results from a ...
Shockwave Medical Inc. will acquire Neovasc Inc. for just under $108 million, if all terms of the deal are met. Shockwave will pay $27.25 in cash for each of Neovasc’s 2.71 million outstanding shares ...
VANCOUVER and MINNEAPOLIS, July 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), announced today that it has been informed by the U.S.
VANCOUVER, - Neovasc Inc., a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment ...
VANCOUVER, June 27, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement ...
ATLANTA -- For people with stable coronary artery disease and refractory angina, a coronary sinus reducer (CSR) implant showed a symptom alleviation benefit in the small placebo-controlled ...
More than 10 hours of testimony and debate failed to convince a US Food and Drug Administration (FDA) expert advisory panel that existing evidence reasonably supports a premarket approval (PMA) ...
VANCOUVER, July 12, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback